About this trial
Human splenic physiology remains poorly understood due to lack of functional exploration. However, through its ability to recognize alterations or modifications in circulating cells and to trigger an innate and adaptive response in response to these anomalies, the spleen plays a central role in several diseases affecting blood cells, directly or indirectly. The analysis of the splenic clearance of abnormal cells during ex-vivo perfusions made it possible to clarify the pathogenesis of malaria and the role of the spleen in the adaptive immune response. The study's investigative team wishes to extend these explorations to other human diseases in which the spleen is involved, and to evaluate the preventive or curative potential of substances that can modify the perception of blood cells by the spleen (e.g. monoclonal antibodies directed against circulating cells, among other options).
Eligibility criteria
Qualifiers
Adult patients
Patient requiring left splenopancreectomy or planned splenectomy regardless of the method or indication
Disqualifiers
None
Trial design
Treatments tested in this trial
- Spleen, blood and plasma collection
Treatment groups
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Institut Pasteur
Collaborator
URC-CIC Paris Descartes Necker Cochin
Collaborator